Table 2

 Remissions, flares, withdrawals, and adverse events in two trials of etanercept in Wegener’s granulomatosis*

Stone et al23Wegener’s Granulomatosis Etanercept Trial26
Etanercept(n = 20)Placebo(n = 91)Etanercept(n = 89)p value†
*Values outside parentheses represent the number of patients or the number of events in the case of flares and values in parentheses represent percentages.
†p values calculated compare the two arms of the Wegener’s Granulomatosis Etanercept Trial.
NA, not applicable; ND, no data available.
Total remissions achieved16 (80)84 (92)80 (90)0.35
Sustained remission (for 6 months)NA64 (75)62 (70)0.39
No of severe flares (organ or life threatening events)320270.87
Withdrawals1 (5)34 (36)35 (39)ND
Severe adverse events0 (0)(57)(56)0.9